Epinephrine autoinjectors: individualizing device and dosage to optimize anaphylaxis management in the community setting
Anaphylaxis is the most severe manifestation of a systemic allergic reaction, and, in the community setting, the immediate administration of an epinephrine autoinjector (EAI) can be life-saving. Physicians are tasked with selecting the most appropriate EAI for each individual and counseling patients and/or their caregivers to maximize the likelihood of successful deployment of the EAI.
Objective:
To offer an evidence-based expert clinical perspective on how physicians might best tailor EAI selection to their patients with anaphylaxis.
Methods:
A group of eight adult and pediatric allergists with expertise in anaphylaxis management reviewed and assessed the published data and guidelines on anaphylaxis management and EAI device selection.
Results:
Personalized EAI selection is influenced by intrinsic individual factors, extrinsic factors such as the properties of the individual EAI (e.g., dose, needle length, overall design) as well as cost and coverage. The number and the variety of EAIs available have expanded in most jurisdictions in recent years, which provide a greater diversity of options to meet the characteristics and needs of patients with anaphylaxis.
Conclusion:
There currently are no EAIs with customizable dose and needle length. Although precise personalization of each patient's EAI remains an optimistic future aspiration, careful consideration of all variables when prescribing EAIs can support optimal management of anaphylaxis.
Keywords: adrenaline; anaphylaxis; anaphylaxis guidelines; autoinjector; biphasic reaction; device; dosage; epinephrine; risk factors; severe allergic reaction
Document Type: Research Article
Affiliations: 1: From the Division of Clinical Immunology and Allergy, Department of Medicine, Western University, London, Ontario, Canada 2: Division of Allergy and Clinical Immunology, McGill University, Montreal, Quebec, Canada 3: Department of Pediatrics and Emergency Medicine, University of Ottawa, Ottawa, Ontario, Canada 4: Division of Allergy and Immunology, Department of Medicine, Queen's University, Kingston, Ontario, Canada, and 5: Pediatric Allergy and Clinical Immunology, University of British Columbia, Vancouver, British Columbia, Canada 6: Clinical Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
Publication date: January 1, 2023
- Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.
The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma and by having the potential to directly impact the quality of patient care. AAP welcomes the submission of original works including peer-reviewed original research and clinical trial results. Additionally, as the official journal of the Eastern Allergy Conference (EAC), AAP will publish content from EAC poster sessions as well as review articles derived from EAC lectures.
Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
Articles marked "F" offer free full text for personal noncommercial use only.
The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service. - Editorial Board
- Information for Authors
- Submit a Paper
- Information for Advertisers
- Reprint Requests
- Commercial level: Permission to use content
- www.JFoodAllergy.com
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content